This year HCPCS brings a slew of deletions, streamlining your drug coding choices. Although these changes have a positive side, there are always considerations that'll crop up.
This year HCPCS brings a slew of deletions, streamlining your drug coding choices. Among the affected drugs, mention may be made of Cisplatin, cyclophosphamide, and vincristine. This change should ease your billing, more so if the system your practice or facility uses limits you to a single code and billable unit for a drug.
Watch out: These changes have a positive side; however there are always considerations that'll crop up. For instance, if your practice uses different vial sizes, you will need to be on your toes for the different and specific national drug code numbers for the agent dispensed to the patient when you send a claim to a payer who needs national drug code information.
J9060 for Cisplatin
Cisplatin, particularly ordered for patients with metastatic testicular or ovarian neoplasms, or advanced bladder cancers, is one of the many agents affected by the HCPCS 2011 shake-up.
This year HCPCS makes a small wording revision to J9060: While last year it was J9060 -- Injection, cisplatin, powder or solution, per 10 mg. this year it's J9060 -- Injection, cisplatin, powder or solution, 10 mg.
To add to these, Code J9062 is no longer available this year. In the end, you should use J9060 to report cisplatin, brand name Platinol, when supplied for 2011 DOS.
Yet another antineoplastic impacted by the HCPCS revisions is cytarabine, which works to stop DNA replication. However liposomal form: J9098 is here to stay as HCPCS 2011 keeps the code. This form is also called DepoCyt and can be used in intrathecal administration. You'll also still have one code for the non-liposomal form (Cytosar-U): J9100. But then HCPCS 2011 deletes the other non-liposomal code, J9110.
For further details on this year's medical coding sign up for a one-stop HCPCS codes guide like Supercoder.
Watch out: These changes have a positive side; however there are always considerations that'll crop up. For instance, if your practice uses different vial sizes, you will need to be on your toes for the different and specific national drug code numbers for the agent dispensed to the patient when you send a claim to a payer who needs national drug code information.
J9060 for Cisplatin
Cisplatin, particularly ordered for patients with metastatic testicular or ovarian neoplasms, or advanced bladder cancers, is one of the many agents affected by the HCPCS 2011 shake-up.
This year HCPCS makes a small wording revision to J9060: While last year it was J9060 -- Injection, cisplatin, powder or solution, per 10 mg. this year it's J9060 -- Injection, cisplatin, powder or solution, 10 mg.
To add to these, Code J9062 is no longer available this year. In the end, you should use J9060 to report cisplatin, brand name Platinol, when supplied for 2011 DOS.
Yet another antineoplastic impacted by the HCPCS revisions is cytarabine, which works to stop DNA replication. However liposomal form: J9098 is here to stay as HCPCS 2011 keeps the code. This form is also called DepoCyt and can be used in intrathecal administration. You'll also still have one code for the non-liposomal form (Cytosar-U): J9100. But then HCPCS 2011 deletes the other non-liposomal code, J9110.
For further details on this year's medical coding sign up for a one-stop HCPCS codes guide like Supercoder.
